Glovista Investments’s Bristol-Myers Squibb BMY Stock Holding History

Glovista Investments’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-25,785	Closed	-$1.99M	–	37
2022 Q2	$1.99M	Sell	25,785 -133	-0.5%	-$10.1K	0.82%	25
2022 Q1	$1.89M	Buy	+25,918	New	+$1.74M	0.56%	32
2015 Q2	–	Sell	-3,135	Closed	-$202K	–	73
2015 Q1	$202K	Buy	+3,135	New	+$196K	0.02%	77

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Glovista Investments's BMY Position: Q3 2022 in Review

Glovista Investments sold out of Bristol-Myers Squibb (BMY) in Q3 2022, closing a stake of 25,785 shares — an estimated $1.99M sold.

Glovista Investments first reported a position in BMY in Q1 2015 and held it in 3 quarters. The position peaked at $1.99M in Q2 2022. 2,469 funds tracked by Wall St. Rank hold BMY as of Q3 2022.

Glovista Investments reported no remaining Bristol-Myers Squibb position as of Q3 2022 after selling out during the quarter.
Glovista Investments sold 25,785 Bristol-Myers Squibb shares in Q3 2022, an estimated $1.99M.
Glovista Investments first reported a position in Bristol-Myers Squibb in Q1 2015 and held it in 3 quarters.
Glovista Investments's Bristol-Myers Squibb position peaked at $1.99M in Q2 2022.
2,469 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.

Based on Glovista Investments's 13F filing for Q3 2022, filed 14 Nov 2022.